Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
444 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00252746 | ZD6474 Phase IIa Dose Finding Multicentre Study | completed | Phase 2 | 53 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 25, 2016 | clinicaltrials |
| NCT00499850 | Phase I FOLFOX Combination | completed | Phase 1 | 18 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 25, 2016 | clinicaltrials |
| NCT00506051 |
| ZD6474(Vandetanib) + Alimta Combo Study |
| completed |
| Phase 1 |
| 21 |
| Genzyme, a Sanofi CompanyINDUSTRY |
| 0 |
| Aug 25, 2016 |
| clinicaltrials |
| NCT00507091 | Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Aug 25, 2016 | clinicaltrials |
| NCT00034918 | This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer | completed | Phase 2 | 44 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Aug 24, 2016 | clinicaltrials |
| NCT00047788 | Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer | completed | Phase 2 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Aug 24, 2016 | clinicaltrials |
| NCT00059722 | This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | completed | Phase 2 | 160 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Aug 24, 2016 | clinicaltrials |
| NCT00066313 | ZD6474 in Treating Patients With Small Cell Lung Cancer | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 24, 2016 | clinicaltrials |
| NCT01362972 | Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor | completed | — | 7,801 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Aug 24, 2016 | clinicaltrials |
| NCT01751308 | Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 39 | SanofiINDUSTRY | 2 | Aug 12, 2016 | clinicaltrials |
| NCT00046683 | Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia | completed | Phase 3 | 284 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jul 28, 2016 | clinicaltrials |
| NCT01511536 | Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 38 | SanofiINDUSTRY | 3 | Jul 28, 2016 | clinicaltrials |
| NCT00519285 | Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer(VENICE) | completed | Phase 3 | 1,224 | SanofiINDUSTRY | 31 | Jul 22, 2016 | clinicaltrials |
| NCT01649635 | Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer(PROSPECTA) | completed | Phase 4 | 45 | SanofiINDUSTRY | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00422682 | A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors | completed | Phase 1 | 136 | SanofiINDUSTRY | 1 | Jun 10, 2016 | clinicaltrials |
| NCT00327171 | Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer | completed | Phase 2 | 218 | SanofiINDUSTRY | 11 | Jun 7, 2016 | clinicaltrials |
| NCT00574275 | Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer(VANILLA) | terminated | Phase 3 | 546 | SanofiINDUSTRY | 24 | Jun 7, 2016 | clinicaltrials |
| NCT00851084 | Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer(AFFIRM) | completed | Phase 2 | 268 | SanofiINDUSTRY | 7 | Jun 7, 2016 | clinicaltrials |
| NCT00417209 | Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen(PAPRIKA) | completed | Phase 3 | 408 | SanofiINDUSTRY | 21 | Jun 3, 2016 | clinicaltrials |
| NCT01013324 | Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma | completed | Phase 2 | 67 | SanofiINDUSTRY | 2 | Jun 3, 2016 | clinicaltrials |
| NCT01042925 | Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | completed | Phase 1 / Phase 2 | 42 | SanofiINDUSTRY | 2 | Jun 3, 2016 | clinicaltrials |
| NCT01082068 | Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer | completed | Phase 1 / Phase 2 | 72 | SanofiINDUSTRY | 3 | Jun 3, 2016 | clinicaltrials |
| NCT02074137 | Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer | completed | Phase 4 | 10 | SanofiINDUSTRY | 1 | Jun 2, 2016 | clinicaltrials |
| NCT00174837 | TRACE: Tirapazamine-Radiation And Cisplatin Evaluation(TRACE) | completed | Phase 3 | 317 | SanofiINDUSTRY | 17 | May 26, 2016 | clinicaltrials |
| NCT00602745 | S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen(S-1 Pancreas) | terminated | Phase 3 | 61 | SanofiINDUSTRY | 17 | May 26, 2016 | clinicaltrials |
| NCT00327743 | Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 34 | SanofiINDUSTRY | 2 | May 18, 2016 | clinicaltrials |
| NCT00644124 | Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma | completed | Phase 1 | 25 | SanofiINDUSTRY | 1 | May 6, 2016 | clinicaltrials |
| NCT00387907 | Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer | completed | Phase 2 | 6 | SanofiINDUSTRY | 1 | May 5, 2016 | clinicaltrials |
| NCT00603577 | Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens(XENON) | terminated | Phase 3 | 102 | SanofiINDUSTRY | 8 | May 5, 2016 | clinicaltrials |
| NCT00625664 | Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer(CILAB) | completed | Phase 3 | 337 | SanofiINDUSTRY | 19 | May 5, 2016 | clinicaltrials |
| NCT00876044 | A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients(QUTIE) | completed | Phase 1 | 88 | SanofiINDUSTRY | 7 | May 5, 2016 | clinicaltrials |
| NCT00305188 | Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. | completed | Phase 3 | 879 | SanofiINDUSTRY | 13 | May 4, 2016 | clinicaltrials |
| NCT01943838 | A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 18 | SanofiINDUSTRY | 1 | Apr 22, 2016 | clinicaltrials |
| NCT01955629 | Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient(AMOR) | terminated | Phase 1 / Phase 2 | 4 | SanofiINDUSTRY | 1 | Apr 18, 2016 | clinicaltrials |
| NCT00613509 | Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma | terminated | Phase 2 | 23 | Sanofi Pasteur, a Sanofi CompanyINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT01391533 | Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors(SARMET) | completed | Phase 1 | 72 | SanofiINDUSTRY | 4 | Apr 13, 2016 | clinicaltrials |
| NCT01357330 | Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 18 | SanofiINDUSTRY | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02221492 | Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma | completed | Phase 2 | 32 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 30, 2016 | clinicaltrials |
| NCT02435121 | A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification | completed | Phase 2 | 1 | SanofiINDUSTRY | 1 | Mar 23, 2016 | clinicaltrials |
| NCT00813956 | A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer | completed | Phase 2 | 80 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01033123 | A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | completed | Phase 2 | 41 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01033292 | A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | completed | Phase 2 | 43 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01082549 | Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)(ECLIPSE) | completed | Phase 3 | 780 | SanofiINDUSTRY | 14 | Mar 17, 2016 | clinicaltrials |
| NCT01173497 | A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis | completed | Phase 2 | 44 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01403636 | A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia | completed | Phase 2 | 167 | SanofiINDUSTRY | 6 | Mar 17, 2016 | clinicaltrials |
| NCT01985191 | A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients | completed | Phase 1 | 26 | SanofiINDUSTRY | 2 | Feb 25, 2016 | clinicaltrials |
| NCT01657214 | Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients(SARMETA) | completed | Phase 1 | 70 | SanofiINDUSTRY | 2 | Feb 17, 2016 | clinicaltrials |
| NCT00699517 | A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies | completed | Phase 3 | 355 | SanofiINDUSTRY | 10 | Dec 21, 2015 | clinicaltrials |
| NCT01263886 | Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer(DISRUPT) | completed | Phase 2 | 176 | SanofiINDUSTRY | 13 | Dec 21, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials